Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis ... Wall Street Journal DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells that can play a key role in MS without causing general immune cell depletion. Biogen Idec to present new drug data at ECTRIMS 2013 |
